AnGes, Inc. has entered a collaboration agreement with Brickell Biotech, Inc., a clinical-stage pharmaceutical company, under which Brickell has the right to develop AnGes’ investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets. AnGes is currently conducting Phase 1/2 clinical studies in Japan, with data expected through 1Q21. The results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.

AnGes will continue to lead the development of its vaccine candidate in Japan and Brickell will provide information and know-how that could be relevant to such development efforts. In exchange, Brickell has the right to develop and, if approved, commercialize AnGes’ DNA vaccine in the U.S. and certain underserved countries.

“We are excited by the opportunity to work with AnGes, a leading vaccine developer in Japan, to potentially bring a COVID-19 vaccine to the U.S. and other countries to help address the global pandemic. AnGes is at the forefront of developing a vaccine for COVID-19 and was the first company in Japan to initiate a COVID-19 vaccine clinical study,” commented Robert Brown, Chief Executive Officer of Brickell. “While Brickell remains firmly focused on initiating its U.S. Phase 3 pivotal program for sofpironium bromide for the treatment of primary axillary hyperhidrosis later this year, we look forward to reviewing AnGes’ clinical study results and then working together with them and the FDA to determine the best path forward.”